IL17A and melanoma: The IRs of melanoma seem to be comparable across patients treated with newer drugs (IL-17 inhibitors, IL-23 inhibitors, JAK inhibitors), and they similarly correspond to the previously published findings concerning patients receiving TNF-α inhibitors.